This may be the first approval of the new FDA- AbbVie announces FDA approval of Rinvoq for treatment of GCA » 07:31 ABBV
SoFi Technologies raises FY25 GAAP EPS view to 27c-28c from 25c-27c » 07:27 SOFI Corning reports Q1 core EPS 54c, consensus 51c 07:29 GLW JetBlue sees softened demand for off-peak travel to continue in Q2 » 07:09 JBLU PayPal reports Q1 adjusted EPS $1.33, consensus $1.16 » 07:02 PYPL Honeywell sees Q2 adjusted EPS $2.60-$2.70, consensus $2.21 » 06:51 HON Roche granted FDA BDD for VENTANA TROP2 RxDx Device » 06:25 RHHBY Clarivate reports Q1 adjusted EPS 14c, consensus 12c » 06:07 CLVT Magnite initiated with bullish view at Rosenblatt, here's why » 22:11 MGNI
MGNI is a name we have wanted to enter. SmartStop Self Storage initiated with bullish view at National Bank, here's why » 21:56 SMA We have favored CUBE in same sector.
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald » 16:25 PRQR Two Harbors reports Q1 EPS 62c, consensus 40c » 16:18 TWO Apellis initiated with bullish view at Cantor Fitzgerald » 16:14 APLS Leggett & Platt reports Q1 adjusted EPS 24c, consensus 22c » 16:12 LEG Cantor starts BioCryst with an Overweight on confidence in Orladeyo » 16:11 BCRX GBA Upgrade-->TWO Two Harbors Investment Corp.- 15% yield???????? $12.00 0.23(+1.95%)4:00 PM 04/28/25 NYSE |$USD |Pre-Market:$12.37+0.37(+3.08%) Company Profile Two Harbors Investment Corp. invests in, finances, and manages mortgage servicing rights (MSRs), agency residential mortgage-backed securities (RMBS), and other financial assets through RoundPoint in the United States. The company target assets include agency RMBS collateralized by fixed rate mortgage loans, adjustable rate mortgage loans, hybrid mortgage loans, or derivatives; and other assets, such as financial and mortgage-related assets, comprising non-agency securities and non-hedging transactions. It qualifies as a REIT for federal income tax purposes. As a REIT, the company must distribute at least 90% of annual taxable income to its stockholders. Two Harbors Investment Corp. was incorporated in 2009 and is headquartered in Saint Louis Park, Minnesota.
Here is another offshoot of our BEAM idea (already VERV)-::: Company Profile Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
GET THIS FREAKIN' DEAL DONE --!! NEW DELHI -New Delhi is prepared to include a sweetener in trade talks with Washington that would "future-proof" a deal by ensuring no other trade partners could have superior terms, as it pushes for a quick agreement with the Trump administration, Indian government officials said.
ENOUGH WITH THE DRAG SHOWS.. ENOUGH WITH THE MAKEUP, -->FOCUS !!! U.S. Treasury Secretary Scott Bessent said on Monday that India could be one of the first to sign a trade deal with the U.S., possibly as soon as this week or next, although he gave no further details. Statements from the Trump administration have said the two sides already agreed on a roadmap for trade discussions.
Shift4 Payments raises FY25 adjusted EBITDA view to $840M-$865M from $830M-$855M » 07:58 FOUR Shift4 Payments reports Q1 adjusted EPS $1.07 vs. 95c last year » 07:56 FOUR Reports Already a GBA holding. FOUR Shift4 Payments, Inc. $79.66-0.62(-0.77%)4:00 PM 04/28/25 NYSE |$USD |Pre-Market:$85.01+5.35(+6.72%)8:15 AM